Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal ARSI : Administrasi Rumah Sakit Indonesia Jurnal Ekonomi Kesehatan Indonesia
putri, septiara
Unknown Affiliation
Decision Sciences, Operations Research & Management Economics, Econometrics & Finance Health Professions Medicine & Pharmacology Public Health Social Sciences

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
KELENGKAPAN DAN KETEPATAN WAKTU PENGISIAN RESUME MEDIS ≤1X24 JAM OLEH DOKTER DI RSIA SMB TAHUN 2020 Savitri, Febriana; Putri, Septiara
Jurnal ARSI : Administrasi Rumah Sakit Indonesia
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The discharge summary is a resume of all patient care and treatment periods that must be filled in entirely by the doctor in charge within 1x24 hours after the patient is pronounced discharged. This study examines the completeness and timeliness of filling in discharge summaries by using the system approach. This research is a qualitative study to obtain input and transformation through in-depth interviews and review of hospital documents, then reinforced with quantitative research to get an overview of the output through observation and study of discharge summary forms. Sixty one discharge summary forms were used as research samples by calculating total sampling. The results showed that the percentage of discharge summaries included in the category fulfilled was only 16.4%. At the same time, in terms of timeliness, it was found that only 45.9% of filling discharge summaries were included in the appropriate time accuracy category. The average time needed for a doctor to get a discharge summary is 32.3 hours. The patient identity and the nursing data items group had the lowest filling distribution, while the highest was in the medical data and data authentication group. There are still differences in knowledge in filling out discharge summary, lack of motivation of the doctors, form formats evaluation that has not been carried out routinely; there is no reward system, punishment system and special training for discharge summary, differences in perceptions regarding the flow of the discharge summary filling process, and the discovery of conflicts related to communication.
Application of Decision Analytic Model in Health Economic Evaluation: Smoking Cessation Cases Putri, Septiara
Jurnal Ekonomi Kesehatan Indonesia Vol. 1, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Health economic evaluation that encompasses decision analytic model is a beneficial approach for assisting decision maker to choose the best health intervention for patients. Decision analytic model has been increasingly applied in health economic evaluation. This mathematical approach is mostly used for conducting cost-effectiveness of healthcare interventions. Decision tree and Markov model has been widely applied in the past 20 years. Decision tree is the simplest form of decision model that drawn by the series of branches and clear pathways. Meanwhile, Markov model is one of the powerful approaches that employ stochastic process in health economic evaluation. This paper describes the applications of those two models in tobacco cessations, specifically for pharmacological interventions. First, decision tree for cost-effectiveness of smoking cessation program with pharmacist and therapies interventions compared to no program or self-aid cessation. Second, the application of Markov model estimates cost-effectiveness of veranicline, in comparison to bupropion. Markov model is constructed with morbidity and mortality states that consists of: well/no morbidities, lung cancer, COPD, stroke, myocardial infarction, and dead. This paper provides step by step of populating and constructing the model-with some modification of data. Several sections discuss the understanding of transition probabilities, costs data cohort simulation, and the role of sensitivity analysis. Other models, despite deterministic approach, probabilistic approach are also reviewed. Both of models had both advantages and limitation that analysts should be aware of. Translating the ‘real world’ to mathematical model yields beneficial and insightful information for analysts. In addition, it could fulfill the need of evidence-based policy by decision maker. From simulation, the model may easy to be replicated-with appropriate context to generate evidence related health and costs.
Economic Evaluation Of Cetuximab for Metastatic Colorectal Cancer (mCRC): A Protocol For Evidence Synthesis Putri, Septiara; Setiawan, Ery; Saldi, Siti Rizny F.; Chandra, Levina; Megraini, Amila; P, Vetty Yulianty
Jurnal Ekonomi Kesehatan Indonesia Vol. 3, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Colorectal cancer is fairly common compared to other cancers. The incidence and mortality rates are predicted to increase globally. In some cases, cancer can be potentially spread to another organ or metastatic. One of recent available targeted therapies for metastatic colorectal cancer (mCRC) patient is Cetuximab (Erbitux ®), combined with chemotherapy. Despite clinical effectiveness, there is the importance of the evidence related cost-effectiveness of therapy. This study aims to summary, synthesize, and systematically review the economic evaluation studies of Cetuximab for metastatic colorectal cancer (mCRC). Model based economic evaluation of Cetuximab for metastatic colorectal cancer will be searched and included in the review based on specific eligibility criteria. Several electronic databases that will be used: Medline, Embase, Cochrane, National Institute of Health Research (NIHR) Center for Reviews and Dissemination. Full economic evaluation evidence will be summarized and critically appraised using Drummond as well as (Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. In terms of analysis, we will qualitatively appraise and present the studies that meet our inclusion and exclusion criteria. We are expected to summarize the quality and capture the valuable insights related to health economic evaluation studies of Cetuximab for mCRC patient.
Co-Authors Chandra, Levina Ery setiawan Megraini, Amila P, Vetty Yulianty Saldi, Siti Rizny F. Savitri, Febriana